title: [Orientated management towards reperfusion in the acute phase of myocardial infarction. Results in a cohort of 700 consecutive patients].
abstract: The principal objective of treatment of the acute phase of myocardial infarction is the obtention of TIMI 3 complete patency. Usually, only a minority of patients receives thrombolytic therapy and complete reperfusion in unusual. Between June 1988 and April 1996, 700 consecutive patients were admitted to Bichat hospital within 6 hours of the onset of transmural myocardial infarction (81% men; age 59 +/- 13 years). The objective of treatment was to obtain maximal coronary patency in the acute phase, either by thrombolysis (with systematic angiography at 90 minutes and salvage angioplasty in case of failure), or primary angioplasty or conventional treatment (usually in cases of spontaneous reperfusion). The emergency angiography and angioplasty procedures were performed by a medical team on 24 hour duty. During the acute phase, 316 patients received intravenous thrombolysis (angiography at 90' in 302 patients with salvage angioplasty in 79 patients), 304 underwent primary angioplasty (TIMI 3 artery in 85% of cases) and 80 underwent conventional treatment (including 52 cases of angiographically documented spontaneous reperfusion). Therefore, a 81% (566/700) rate of patent TIMI 3 arteries was obtained. The hospital mortality was 8.9%, lower in TIMI 3 arterial patency (6%) than TIMI 2 (20%) or TIMI 0-1 (23%), p < 0.001. The mortality was 4% in patients treated by thrombolysis. Therefore, a reperfusion strategy associating thrombolysis and/or angioplasty provides a high TIMI 3 patency rate in the acute phase of myocardial infarction with a low mortality (6%) in consecutive, unselected patients.
authors.affiliation: Service de cardiologie, hôpital Bichat, Paris.
authors.forename: J M
authors.initials: JM
authors.lastname: Juliard
authors.forename: D
authors.initials: D
authors.lastname: Himbert
authors.forename: P
authors.initials: P
authors.lastname: Aubry
authors.forename: H
authors.initials: H
authors.lastname: Benamer
authors.forename: G J
authors.initials: GJ
authors.lastname: Karrillon
authors.forename: A
authors.initials: A
authors.lastname: Boccara
authors.forename: L J
authors.initials: LJ
authors.lastname: Feldman
authors.forename: P G
authors.initials: PG
authors.lastname: Steg
mesh_terms: D000368:Aged; D016009:Chi-Square Distribution; D015331:Cohort Studies; D000075202:Contraindications; D017023:Coronary Angiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005602:France; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000379:methods*; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents
vernacular_title: Prise en charge orientée vers la reperfusion en phase aiguë d'infarctus du myocarde. Résultats sur une cohorte de 700 patients consécutifs.